|Bid price||2.10||Open price||2.15|
|Ask price||2.30||Prev close||2.20|
Register now for FREE live ReNeuron Group share prices, ReNeuron Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get ReNeuron Group Level 2 Data, indepth research tools and investor commentary for ReNeuron Group (RENE) and other London Stock Exchange equities.
Register now for FREE ReNeuron Group share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00B0DZML60|
|Activites||ReNeuron Group plc s a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered 'off-the-shelf' to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. The Company is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina. ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcellÂ®products for use in academic and commercial research. The Company's ReNcellÂ®CX and ReNcellÂ®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.||Index||n/a|
|Latest Share Price (p)||2.20||Net Gearing (%)||-18.41|
|Market Capitalisation (£m)||68.04||Gross Gearing (%)||5.84|
|Shares in issue (m)||3,164.62||Debt Ratio||0.00|
|P/E Ratio||-5.38||Debt-to-Equity Ratio||0.00|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.06|
|Dividend Yield (%)||0.00||Price to book value||1.01|
|Dividend cover (x)||0.00||ROCE (%)||-18.99|
|Earning per share (p)||-0.40||EPS Growth (%)||20.00|
|52 week high / low||3.70 / 2.03||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
ReNeuron Group has reported very significant positive developments with its retinal disease programme. "The successful development of a cryopreserved formulation of our hRPC retinal cell therapy candidate enables an expansion of our clinical programmes in ophthalmology and also gives ReNeuron...
ReNeuron Group says it expects to be able to begin a Phase III study with its CTX cell therapy candidate in stroke disability in H2 2017. "We look forward to reporting further progress over the months ahead," said CEO Olav Hellebo in a statement. "There are currently no therapeutic...
Story provided by StockMarketWire.com
Register now for FREE ReNeuron Group company news
Think this one could have the potetial to be really big... Check out the company info and post any thoughts you have... has massive potential
INVESTORS FUNDS WILL BE SEIZED
Register now for FREE ReNeuron Group share price discussions